See the published version of this preprint at Pediatric Rheumatology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Rosemary Peterson
Dell Children's Medical Center of Central Texas
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0959-2343
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Glucocorticoid exposure is a significant driver of morbidity in children with systemic juvenile idiopathic arthritis (sJIA). We determined the effect of early initiation of biologic therapy (IL-1 or IL-6 inhibition) on glucocorticoid exposure in hospitalized patients with new-onset sJIA.
Methods: We emulated a pragmatic sequence of trials (“pseudo-trials”) of biologic initiation in children (≤ 18 years) hospitalized with new-onset sJIA utilizing retrospective data from an administrative database from 52 tertiary care children’s hospitals from 2008-2019. Eligibility window, treatment assignment and start of follow-up between biologic and non-biologic study arms were aligned for each pseudo-trial. Patients in the source population could meet eligibility criteria at several timepoints. Mixed-effects logistic regression was used to determine the effect of biologic initiation on in-hospital glucocorticoid exposure.
Results: 468 children met eligibility criteria, of which 19% received biologic therapy without preceding or concomitant initiation of immunomodulatory medications. This proportion significantly increased over time during the study period (p < 0.01). 1451 trial subjects were included across 4 pseudo-trials with 71 assigned to the biologic arm and 1409 assigned to the non-biologic arm. After adjustment, there was a trend toward decreased odds of glucocorticoid initiation in the biologic arm compared to the non-biologic arm (OR 0.39, 95% CI [0.13, 1.15]).
Conclusion: Biologic initiation in children hospitalized with new-onset sJIA significantly increased over time and may be associated with reduced glucocorticoid exposure. The increasing use of first-line biologic therapy may lead to clinically relevant reductions in treatment-related adverse effects of glucocorticoid-reliant therapeutic approaches.
Keywords
Juvenile Systemic Arthritis, Biological Therapy, Glucocorticoids
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Pediatric Rheumatology.
Version 1
Posted 28 Dec, 2020
No community comments so far
Editorial decision: Major revision
On 26 Feb, 2021
Review #8 received
Received 25 Feb, 2021
Review #5 received
Received 22 Feb, 2021
Review #6 received
Received 22 Feb, 2021
Reviewer #8 agreed
On 08 Feb, 2021
Reviewer #7 agreed
On 08 Feb, 2021
Review #7 received
Received 08 Feb, 2021
Review #4 received
Received 08 Feb, 2021
Reviewer #6 agreed
On 07 Feb, 2021
Reviewer #5 agreed
On 07 Feb, 2021
Review #2 received
Received 05 Feb, 2021
Review #3 received
Received 05 Feb, 2021
Review #1 received
Received 04 Feb, 2021
Reviewer #4 agreed
On 24 Jan, 2021
Reviewer #2 agreed
On 23 Jan, 2021
Reviewer #3 agreed
On 23 Jan, 2021
Reviewer #1 agreed
On 23 Jan, 2021
Reviewers invited
Invitations sent on 22 Jan, 2021
Editor assigned
On 16 Dec, 2020
Submission checks complete
On 16 Dec, 2020
Editor invited
On 16 Dec, 2020
First submitted
On 15 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
See the published version of this preprint at Pediatric Rheumatology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Rosemary Peterson
Dell Children's Medical Center of Central Texas
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0959-2343
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Pediatric Rheumatology.
Version 1
Posted 28 Dec, 2020
No community comments so far
Editorial decision: Major revision
On 26 Feb, 2021
Review #8 received
Received 25 Feb, 2021
Review #5 received
Received 22 Feb, 2021
Review #6 received
Received 22 Feb, 2021
Reviewer #8 agreed
On 08 Feb, 2021
Reviewer #7 agreed
On 08 Feb, 2021
Review #7 received
Received 08 Feb, 2021
Review #4 received
Received 08 Feb, 2021
Reviewer #6 agreed
On 07 Feb, 2021
Reviewer #5 agreed
On 07 Feb, 2021
Review #2 received
Received 05 Feb, 2021
Review #3 received
Received 05 Feb, 2021
Review #1 received
Received 04 Feb, 2021
Reviewer #4 agreed
On 24 Jan, 2021
Reviewer #2 agreed
On 23 Jan, 2021
Reviewer #3 agreed
On 23 Jan, 2021
Reviewer #1 agreed
On 23 Jan, 2021
Reviewers invited
Invitations sent on 22 Jan, 2021
Editor assigned
On 16 Dec, 2020
Submission checks complete
On 16 Dec, 2020
Editor invited
On 16 Dec, 2020
First submitted
On 15 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Pediatric Rheumatology.
Background: Glucocorticoid exposure is a significant driver of morbidity in children with systemic juvenile idiopathic arthritis (sJIA). We determined the effect of early initiation of biologic therapy (IL-1 or IL-6 inhibition) on glucocorticoid exposure in hospitalized patients with new-onset sJIA.
Methods: We emulated a pragmatic sequence of trials (“pseudo-trials”) of biologic initiation in children (≤ 18 years) hospitalized with new-onset sJIA utilizing retrospective data from an administrative database from 52 tertiary care children’s hospitals from 2008-2019. Eligibility window, treatment assignment and start of follow-up between biologic and non-biologic study arms were aligned for each pseudo-trial. Patients in the source population could meet eligibility criteria at several timepoints. Mixed-effects logistic regression was used to determine the effect of biologic initiation on in-hospital glucocorticoid exposure.
Results: 468 children met eligibility criteria, of which 19% received biologic therapy without preceding or concomitant initiation of immunomodulatory medications. This proportion significantly increased over time during the study period (p < 0.01). 1451 trial subjects were included across 4 pseudo-trials with 71 assigned to the biologic arm and 1409 assigned to the non-biologic arm. After adjustment, there was a trend toward decreased odds of glucocorticoid initiation in the biologic arm compared to the non-biologic arm (OR 0.39, 95% CI [0.13, 1.15]).
Conclusion: Biologic initiation in children hospitalized with new-onset sJIA significantly increased over time and may be associated with reduced glucocorticoid exposure. The increasing use of first-line biologic therapy may lead to clinically relevant reductions in treatment-related adverse effects of glucocorticoid-reliant therapeutic approaches.
Figure 1
Loading...